Launch of Pre-clinical Nuclear Imaging System for Cancer and Neurological Research

Ann Arbor, MI — July 2025 — There is a growing demand from medical research institutions for high resolution, compact imaging tools to better study disease progression in areas such as cancer, cardiovascular and neurodegenerative diseases and to develop novel treatments including radiotherapies.

The first systems from MH3D, US-based innovator in compact pre-clinical single photon emission computed tomography (SPECT/CT), are available now to research institutions.

The systems were made possible from a strategic supply and licensing agreement between MH3D and the UK’s Science and Technology Facilities Council (STFC).

This partnership enables MH3D to integrate STFC’s hyperspectral imaging technology into its next-generation imaging platforms designed for pre-clinical research applications that could inform future drug discovery and patient treatment.

MH3D's imaging systems uses STFC's detector to achieve market leading accuracy in measuring and characterising gamma rays emitted by radiopharmaceuticals, which informs researchers on drug performance.

This collaboration marks a significant step toward advancing the future of medical imaging in pre-clinical research. Supported by a multi-year framework, the partnership strengthens MH3D’s ability to deliver compact, high-resolution imaging systems built on STFC’s proven technology.

Xiaopei Huang, CEO of MH3D, said, “Our core mission at MH3D is to empower researchers with the tools they need to better understand disease mechanisms and therapeutic responses. This partnership with STFC enables us to incorporate world-class technology into our imaging systems, strengthening our position to achieve our goal.”

Matt Wilson, Detector Development Group Lead at STFC’s Technology Department, said, “This exciting partnership enables STFC’s UK designed and built HEXITEC detection technology to be incorporated into MH3D’s cutting edge scanners, driving the development of new therapeutics and ultimately bringing patient benefit.”

Learn More

For more information about MH3D and its innovative solutions, visit mh3dinc.com.

About MH3D Inc. MH3D Inc. is a pioneering medical imaging company based in Ann Arbor, Michigan. Specializing in cutting-edge SPECT technology, MH3D aims to improve patient care and advance scientific research through innovative solutions. A spinout from the University of Michigan, Ann Arbor, and the University of Illinois, Urbana-Champaign, MH3D is at the forefront of transforming imaging technology for clinical and pre-clinical applications.